Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma.
Sorger H, Dey S, Vieyra-Garcia PA, Pölöske D, Teufelberger AR, de Araujo ED, Sedighi A, Graf R, Spiegl B, Lazzeri I, Braun T, Garces de Los Fayos Alonso I, Schlederer M, Timelthaler G, Kodajova P, Pirker C, Surbek M, Machtinger M, Graier T, Perchthaler I, Pan Y, Fink-Puches R, Cerroni L, Ober J, Otte M, Albrecht JD, Tin G, Abdeldayem A, Manaswiyoungkul P, Olaoye OO, Metzelder ML, Orlova A, Berger W, Wobser M, Nicolay JP, André F, Nguyen VA, Neubauer HA, Fleck R, Merkel O, Herling M, Heitzer E, Gunning PT, Kenner L, Moriggl R, Wolf P. Sorger H, et al. Among authors: manaswiyoungkul p. EMBO Mol Med. 2022 Dec 7;14(12):e15200. doi: 10.15252/emmm.202115200. Epub 2022 Nov 7. EMBO Mol Med. 2022. PMID: 36341492 Free PMC article.
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.
Garcha HK, Nawar N, Sorger H, Erdogan F, Aung MMK, Sedighi A, Manaswiyoungkul P, Seo HS, Schönefeldt S, Pölöske D, Dhe-Paganon S, Neubauer HA, Mustjoki SM, Herling M, de Araujo ED, Moriggl R, Gunning PT. Garcha HK, et al. Among authors: manaswiyoungkul p. Pharmaceuticals (Basel). 2022 Oct 26;15(11):1321. doi: 10.3390/ph15111321. Pharmaceuticals (Basel). 2022. PMID: 36355493 Free PMC article.
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, von Jan J, Ianevski A, Gawel JM, Olaoye OO, Geletu M, Abdeldayem A, Israelian J, Radu TB, Sedighi A, Bhatti MN, Hassan MM, Manaswiyoungkul P, Shouksmith AE, Neubauer HA, de Araujo ED, Aittokallio T, Krämer OH, Moriggl R, Mustjoki S, Herling M, Gunning PT. Toutah K, et al. Among authors: manaswiyoungkul p. J Med Chem. 2021 Jun 24;64(12):8486-8509. doi: 10.1021/acs.jmedchem.1c00420. Epub 2021 Jun 8. J Med Chem. 2021. PMID: 34101461 Free PMC article.
Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
Hassan MM, Israelian J, Nawar N, Ganda G, Manaswiyoungkul P, Raouf YS, Armstrong D, Sedighi A, Olaoye OO, Erdogan F, Cabral AD, Angeles F, Altintas R, de Araujo ED, Gunning PT. Hassan MM, et al. Among authors: manaswiyoungkul p. J Med Chem. 2020 Aug 13;63(15):8634-8648. doi: 10.1021/acs.jmedchem.0c01025. Epub 2020 Jul 31. J Med Chem. 2020. PMID: 32672458
A functional in vitro assay for screening inhibitors of STAT5B phosphorylation.
de Araujo ED, Manaswiyoungkul P, Erdogan F, Qadree AK, Sina D, Tin G, Toutah K, Yuen K, Gunning PT. de Araujo ED, et al. Among authors: manaswiyoungkul p. J Pharm Biomed Anal. 2019 Jan 5;162:60-65. doi: 10.1016/j.jpba.2018.08.036. Epub 2018 Aug 18. J Pharm Biomed Anal. 2019. PMID: 30223143
Structural and functional consequences of the STAT5BN642H driver mutation.
de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, Seo HS, Qadree AK, Israelian J, Orlova A, Suske T, Pham HTT, Boersma A, Tangermann S, Kenner L, Rülicke T, Dong A, Ravichandran M, Brown PJ, Audette GF, Rauscher S, Dhe-Paganon S, Moriggl R, Gunning PT. de Araujo ED, et al. Among authors: manaswiyoungkul p. Nat Commun. 2019 Jun 7;10(1):2517. doi: 10.1038/s41467-019-10422-7. Nat Commun. 2019. PMID: 31175292 Free PMC article.
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
Shouksmith AE, Gawel JM, Nawar N, Sina D, Raouf YS, Bukhari S, He L, Johns AE, Manaswiyoungkul P, Olaoye OO, Cabral AD, Sedighi A, de Araujo ED, Gunning PT. Shouksmith AE, et al. Among authors: manaswiyoungkul p. ACS Med Chem Lett. 2019 Dec 13;11(1):56-64. doi: 10.1021/acsmedchemlett.9b00471. eCollection 2020 Jan 9. ACS Med Chem Lett. 2019. PMID: 31938464 Free PMC article.
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma.
Nawar N, Bukhari S, Adile AA, Suk Y, Manaswiyoungkul P, Toutah K, Olaoye OO, Raouf YS, Sedighi A, Garcha HK, Hassan MM, Gwynne W, Israelian J, Radu TB, Geletu M, Abdeldayem A, Gawel JM, Cabral AD, Venugopal C, de Araujo ED, Singh SK, Gunning PT. Nawar N, et al. Among authors: manaswiyoungkul p. J Med Chem. 2022 Feb 24;65(4):3193-3217. doi: 10.1021/acs.jmedchem.1c01585. Epub 2022 Feb 4. J Med Chem. 2022. PMID: 35119267
13 results